<DOC>
	<DOCNO>NCT03020134</DOCNO>
	<brief_summary>The purpose study evaluate Pharmacokinetics safety Ravidasvir Combination Ritonavir-boosted Danoprevir Single Multiple dose Healthy Participants</brief_summary>
	<brief_title>Pharmacokinetics Safety Ravidasvir Danoprevir/r Healthy Volunteers China</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Willing able provide write informed consent Overall health situation good accord disease history , physical exam , physical symptom , laboratory test 12 lead ECG . If female , surgically sterilize willingness use reliable method birth control study 30 day last dose study medication . If male , surgically sterilize willingness use reliable method birth control study 30 day last dose study medication . If female , negative pregnancy test screening period . Others specify detailed protocol History presence cardiovascular disease , respiratory disease , endocrine metabolic system disease , urinary system , digestive system , hematological system disease , nervous system Psychiatric diseases , acute chronic infectious disease malignant tumor . Positive test HAVIgM , HBsAg , HCV Ab , HIV Ab , Syphilis Ab History gastrointestinal surgery , trunk vagotomy , intestinal excision surgery could disturb gastrointestinal motility PH absorption . Female pregnancy , breastfeeding , period unwilling take reliable birth control method . Others specify detailed protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>Danoprevir/r</keyword>
	<keyword>Ravidasvir</keyword>
</DOC>